Save information for later
Sign Up

Learn About Pure Red Cell Aplasia

What is the definition of Pure Red Cell Aplasia?
Pure red cell aplasia (PRCA) is a rare condition that affects the bone marrow. Bone marrow contains stem cells which develop into the red blood cells that carry oxygen through the body, the white blood cells that fight infections, and the platelets that help with blood clotting. In people with PRCA, the bone marrow makes a reduced number of red blood cells (called anemia). As a result, affected people may experience fatigue, lethargy, and pale skin. PRCA has many different causes. A rare congenital form of PRCA, called Diamond Blackfan syndrome, is an inherited condition that is also associated with other physical abnormalities. PRCA can also be due to certain medications, infections, pregnancy, renal failure, and conditions such as thymomas, autoimmune disease (such as systemic lupus erythematosus), cancers of the blood, and solid tumors. In many cases, the cause of the condition is unknown (idiopathic).
What are the alternative names for Pure Red Cell Aplasia?
  • Pure red cell aplasia
  • PRCA
Who are the top Pure Red Cell Aplasia Local Doctors?
Adrianna Vlachos
Elite in Pure Red Cell Aplasia
Hematology | Pediatric Hematology Oncology
Elite in Pure Red Cell Aplasia
Hematology | Pediatric Hematology Oncology

Johns Hopkins All Children's Outpatient Care, St. Petersburg

Saint Petersburg, FL 
Languages Spoken:
English, Greek
Offers Telehealth

Dr. Vlachos is the chief of hematology in the Johns Hopkins All Children’s Hospital Cancer & Blood Disorders Institute in St. Petersburg, Florida, and professor of pediatrics (PAR) in the Johns Hopkins University School of Medicine. She joined the hospital staff in 2024. She was previously professor of pediatrics at Zucker School of Medicine at Hofstra/Northwell and attending physician in hematology/oncology at Cohen Children’s Medical Center/Northwell Health, where she was head of the Bone Marrow Failure Program and head of the pediatric hematology/oncology trials office. Dr. Vlachos is internationally known for clinical care and expertise in bone marrow failure syndromes and her transformational research in Diamond Blackfan anemia (DBA) syndrome, a rare inherited bone marrow failure syndrome. Dr. Vlachos is the founder and has directed the Diamond Blackfan Anemia Registry (DBAR) of North America since its inception in 1991. She is the principal investigator and co-investigator on multiple grants funded by the National Institute of Health and the Centers for Disease Control and Prevention. She has published numerous articles on her research findings and has been invited to author papers and book chapters on bone marrow failure syndromes and DBA. Dr. Vlachos is a member of the Medical and Scientific Advisory Board for the Shwachman-Diamond Syndrome Registry, is a member of the Scientific Advisory Board for the Diamond Blackfan Anemia Foundation and holds a position on the Scientific Program Committee for Bone Marrow Failure of the American Society of Hematology. She earned her medical degree from New York Medical College in Valhalla, New York. She completed her residency in pediatrics at North Shore University Hospital in Manhasset, New York. She then completed a clinical fellowship in bone marrow transplantation at North Shore University Hospital, followed by a fellowship in pediatric hematology-oncology and bone marrow transplantation at Mount Sinai Medical Center in New York. Videos Bone Marrow Failure Syndrome Expert Dr. Adrianna Vlachos at Johns Hopkins All Children’s. Dr. Vlachos is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Aplastic Anemia, and Transient Erythroblastopenia of Childhood.

Jeffrey M. Lipton
Elite in Pure Red Cell Aplasia
Pediatric Hematology Oncology
Elite in Pure Red Cell Aplasia
Pediatric Hematology Oncology

Northwell Health Pediatric Hematology/Oncology & Stem Cell Transplant

269-01 76th Avenue, Suite 255, 
New Hyde Park, NY 
Languages Spoken:
English

Jeffrey Lipton is a Pediatric Hematologist Oncology provider in New Hyde Park, New York. Dr. Lipton is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Transient Erythroblastopenia of Childhood, Aplastic Anemia, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Jaroslaw Maciejewski
Elite in Pure Red Cell Aplasia
Elite in Pure Red Cell Aplasia

Cleveland Clinic

8950 Euclid Ave, 
Cleveland, OH 
Languages Spoken:
English
Offers Telehealth

Jaroslaw Maciejewski is a Hematologist in Cleveland, Ohio. Dr. Maciejewski is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Aplastic Anemia, Paroxysmal Cold Hemoglobinuria, Bone Marrow Transplant, and Splenectomy.

What are the latest Pure Red Cell Aplasia Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study

Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop cancer. These cancer-...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center